跳至主要内容
临床试验/NCT06859255
NCT06859255招募中不适用

In-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation

IRCCS Policlinico S. Donato3 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2025年2月7日最近更新:
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
3
主要终点
Bench tests performance

研究概览

简要总结

The general objective of this study is to compare in vitro and in vivo the hemodynamic performance of different types of aortic valve prostheses and possible surgical implantation techniques.

The study involves the collection of data deriving from tests and procedures foreseen by normal clinical practice, including a transthoracic color Doppler echocardiogram, to which is added a 4DFlow cardiac MRI (magnetic resonance imaging) without contrast medium, to be performed between 1 and 3 months after the operation.

The study will last 24 months and the patients involvement will end approximately 1-3 months after the intervention.

There are no direct benefits expected from participation in the study. However, the instrumental data obtained by echocardiogram and Magnetic Resonance Imaging will be useful for monitoring the medium-term surgical outcome of patients after surgery.

详细描述

The goal of the study is testing hydrodynamic performances of various surgical and transcatheter valve prostheses, also according to the technique of implantation. A dedicated Magnetic Resonance Imaging (MRI) compatible mock circulation simulator will be implemented, including a circuit filled with blood-alike fluid, a pulsatile pump, and 3D printed silicon phantoms of ascending aorta.

Data collection will focus on structural changes of prostheses in response to flow, including leaflet motion, gradients and flows across the valve, taken either by direct pressure measurements and 4D Flow MRI. As second step, trans-valvular gradients and valve performance in patients implanted with the same tested valves will be measured by echocardiogram and 4D Flow MRI.

Degenerative aortic valve stenosis is a common disease in people >65 years, with an estimated rate approaching 10% in Western countries. Despite progress in diagnosis and therapy, invasive treatments still represent the only definitive option, including surgical aortic valve replacement (SAVR) and more recently less-invasive transcatheter aortic valve replacement (TAVR).

Patients with small aortic annulus constitute a challenging subset, where the need to minimize both procedural and longterm risk entwine with that of avoiding patient-prosthesis mismatch (PPM) and structural valve deterioration (SVD). The common denominator appears to be blood flow, which has demonstrated to play a pivotal role in late complications. In fact, PPM is associated with earlier structural valve dysfunction and higher long-term mortality. To obtain larger effective orifice area, surgeons must consider many different procedures (annular enlargement), valve models (stented valves, subcoronary stentless valves, or rapid deployment valves) or different techniques of valve suturing. However, in the literature, there is no clear indication to the ideal strategy of treatment so far. Heart valve prostheses generate turbulent flow in the aortic root and the ascending aorta. Hydrodynamic instabilities and turbulent flow may produce clinically adverse events. Therefore, a thorough evaluation of hemodynamic and flow conditions should be tested, to provide the most effective treatment strategy for each patient.

Both units regularly perform surgical as well as percutaneous aortic valve replacements: patients from both centres will be enrolled to evaluate post-implant valve performances by echocardiogram and MR imaging.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • patients who underwent SAVR or TAVI for severe aortic stenosis
  • implanted with valve models and sizes among those which we evaluated in vitro

排除标准

  • treated or untreated aortic root/ascending aorta aneurysm
  • preoperative aortic regurgitation more than moderate
  • recent (<12 weeks)/ concomitant revascularization
  • recent (<12 weeks) ACS
  • PPI (permanent pacemaker implantation)
  • other than sinus rythm
  • Paravalvular leak (PVL) > moderate.

研究组 & 干预措施

Aortic Valve Replacement Patient

Experimental

Inclusion criteria:

  • evaluation of patients who underwent SAVR or TAVI for severe aortic stenosis
  • implanted with valve models and sizes among those which we evaluated in vitro.

Exclusion criteria:

  • treated or untreated aortic root/ascending aorta aneurysm
  • preoperative aortic regurgitation more than moderate
  • recent (<12 weeks)/ concomitant revascularization or recent (<12 weeks) ACS

Timing of trans-thoracic echocardiography (TTE) and MRI: 1 to 3 months after SAVR/TAVR.

Intervention: MRI, it is not clinical practice during 1 month follow-up. Clinical Variables: in order to reduce clinical bias in the comparison of the two populations, at the moment of TTE exam, blood pressure, heart rate and haemoglobin values will be recorded.

干预措施: MRI (Diagnostic Test)

结局指标

主要结局

Bench tests performance

时间窗: 24 months

Pressure gradient after valve implantation in vitro

MRI in vitro

时间窗: 24 months

Blood flow pattern of aortic in vitro models under 4D flow MRI

RMN in vivo

时间窗: 24 months

Blood flow pattern of implanted valves will be evaluated in vivo through a MRI 4 flow

Echo in vivo

时间窗: 24 months

Morphology of the bioprosthetic valve leaflets will be evaluated in vivo through an Echo

次要结局

未报告次要终点

研究者

发起方
IRCCS Policlinico S. Donato
申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验